Back

Tirzepatide confers superior cardiorenal protection compared to semaglutide in type 2 diabetes: insights from a large-scale propensity-matched real-world cohort

29 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Cardiometabolic pharmacotherapy for cardiovascular risk Antidiabetic Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Ms Iffat Zahan

Harefield Hospital, Harefield (United Kingdom of Great Britain & Northern Ireland)

7 More presentations in this session

Presentation thumbnail
Cardiovascular outcomes across GLP-1/GIP agonists in a large, diverse real-world cohort: the INCRETIN-CV study
Doctor C. Gurevitz (Petah Tikva, IL)
Abstract Slides
Presentation thumbnail
Comparative analysis of monthly weight-regain dynamics after discontinuation of semaglutide vs tirzepatide
Professor G. Fazio (Palermo, IT)
Abstract Slides
Presentation thumbnail
Semaglutide demonstrates favorable safety profile with 43% reduction in serious adverse events in adults with established ASCVD: a systematic review and meta-analysis of randomized controlled trials
Doctor V. Purewal (Scottsdale, US)
Abstract Slides
Presentation thumbnail
Effects of hybrid closed-loop systems and SGLT2i on myocardial deformation and vascular function in type 1 diabetics
Doctor K. Katogiannis (Athens, GR)
Abstract Slides
Presentation thumbnail
Prognostic outcomes of SGLT2 inhibitors versus metformin in patients with type 2 diabetes and acute myocardial infarction
Doctor H. Zhang (Tianjin, CN)
Abstract Slides

Access the full session

Session thumbnail
Cardiometabolic pharmacotherapy for cardiovascular risk

The Event

Event poster

ESC Congress 2026

29 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Empagliflozin use versus dipeptidyl peptidase 4 inhibitors reduces risk of cardiovascular and renal disease among type 2 diabetes patients in routine care in europe and israel: EMPRISE study results
29 June 2021
thumbnail
Congress Presentation
Tirzepatide treatment and achieving weight reduction >5%, SBP reduction >5 mmHg and non-HDL cholesterol reduction >10%: A post hoc analysis from the SURMOUNT-1 3-year trial
30 August 2025
thumbnail
Congress Presentation
Efficacy of semaglutide in reducing atrial fibrillation recurrence post-catheter ablation: propensity score-matched analysis
1 April 2025
thumbnail
Congress Presentation
Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources